U.S. Markets open in 2 hrs 34 mins

OpGen, Inc. (OPGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.5700+0.0700 (+2.80%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.5000
Open2.5500
Bid2.4500 x 800
Ask2.6000 x 1000
Day's Range2.5500 - 2.6600
52 Week Range1.5200 - 5.7600
Volume1,028,993
Avg. Volume3,270,405
Market Cap71.625M
Beta (5Y Monthly)-0.51
PE Ratio (TTM)N/A
EPS (TTM)-1.8690
Earnings DateMar 22, 2021 - Mar 26, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.83
  • Benzinga

    5 Value Stocks In The Healthcare Sector

    Understanding Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be undervalued, as investors are not expressing as much interest in such companies. The most commonly used way to check for value is with the price-to-earnings multiple, or P/E. A low P/E multiple is a good indication that the stock is undervalued. Benzinga Insights has compiled a list of value stocks in the healthcare sector that may be worth watching: Global Cord Blood (NYSE:CO) - P/E: 6.8 RAPT Therapeutics (NASDAQ:RAPT) - P/E: 0.71 OpGen (NASDAQ:OPGN) - P/E: 0.68 Onconova Therapeutics (NASDAQ:ONTX) - P/E: 1.59 Greenlane Holdings (NASDAQ:GNLN) - P/E: 9.89 Global Cord Blood saw an increase in earnings per share from 0.15 in Q1 to 0.16 now. Global Cord Blood does not have a dividend yield, which investors should be aware of when considering holding onto such a stock. RAPT Therapeutics saw a decrease in earnings per share from -0.51 in Q2 to -0.6 now. RAPT Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock. OpGen's earnings per share for Q3 sits at -0.4, whereas in Q2, they were at -0.49. OpGen does not have a dividend yield, which investors should be aware of when considering holding onto such a stock. Onconova Therapeutics has reported Q3 earnings per share at -0.03, which has increased by 25.0% compared to Q2, which was -0.04. Onconova Therapeutics does not have a dividend yield, which investors should be aware of when considering holding onto such a stock. Greenlane Holdings has reported Q3 earnings per share at -0.35, which has increased by 23.91% compared to Q2, which was -0.46. Greenlane Holdings does not have a dividend yield, which investors should be aware of when considering holding onto such a stock. These 5 value stocks were selected by Benzinga Insights based on quantified analysis. While this methodical judgment process is not meant to make final decisions, our technology can give investors additional perception into the sector. See more from BenzingaClick here for options trades from BenzingaUnusual Options Activity Insight: QuantumScapeUnderstanding Exxon Mobil's Unusual Options Activity© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • OpGen Subsidiary Ares Genetics Announces Publication of Study Introducing Best Practice Techniques for AI-powered Prediction of Antibiotic Susceptibility Testing by Next-Generation Sequencing
    GlobeNewswire

    OpGen Subsidiary Ares Genetics Announces Publication of Study Introducing Best Practice Techniques for AI-powered Prediction of Antibiotic Susceptibility Testing by Next-Generation Sequencing

    Study highlights best practice techniques for accurate antimicrobial resistance prediction from whole-genome sequencing data Publication supports harmonization of the development of good machine learning practices as encouraged in recent FDA AI/ML Software as a Medical Device Action Plan Work promotes robustness and facilitates translation of next-generation sequencing based antibiotic susceptibility testing into clinical practice GAITHERSBURG, Md. and VIENNA, Austria, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Ares Genetics GmbH (Vienna, Austria; “Ares Genetics”), a subsidiary of OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today the publication of a peer-reviewed study introducing best practice techniques for prediction of antibiotic susceptibility testing (AST) results from whole-genome sequencing (WGS) data. The work led by Ares Genetics and performed in collaboration with Prof. Thomas Rattei from the Division of Computational Systems Biology at the University of Vienna critically assessed different machine learning (ML) techniques for whole genome sequencing (WGS)-based AST on several thousand genome assemblies across more than 50 species/compound combinations collated from public databases. The publication describes the combination of different machine learning architectures for robust and accurate WGS-based AST. The study addresses two out of five actions stipulated by the FDA in the recently issued Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. It aims at advancing good machine learning practices (GMLP) for WGS-based AST by describing best practice techniques for training and evaluation of predictive models, as well as introducing an optimized model architecture to reduce bias and promote robustness. Dr. Arne Materna, CEO of Ares Genetics, commented, “The present study adds to Ares Genetics’ publication record validating our approach to becoming a globally recognized leader in the development of AI-powered next generation sequencing or NGS-based solutions for infectious disease testing. Addressing the U.S. FDA action plan by developing good machine learning practice and robust algorithms will be key to moving our AI-powered solutions into clinical practice. Applying the proposed best practice techniques to our unique and curated ARESdb allowed us to further improve predictive performance of WGS-based AST even beyond the performance shown in our seminal multi-center evaluation study demonstrating feasibility of WGS-based AST for a broad selection of pathogen-drug combinations. In this context, we are currently also working with several leading clinical centers in the United States to further demonstrate the potential of accurate WGS-based AST in independent validation studies.” Oliver Schacht, President & CEO of OpGen added, “The Ares Technology platform is an integral part of OpGen’s precision medicine offering and complements our commercial FDA-approved Unyvero platform as well as our Acuitas AMR Gene Panel for isolates for which we anticipate an upcoming FDA clearance decision. Following the successful integration of Ares Genetics into OpGen globally, we are focused on executing on our strategy to establish ourselves as industry leaders in the artificial intelligence and bioinformatics space.” About OpGen, Inc. OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. For more information, please visit www.opgen.com. Forward-Looking Statements by OpGen This press release includes statements regarding the recently published benchmarking study on AI-powered prediction of antibiotic susceptibility. These statements and other statements regarding OpGen’s Unyvero products, their commercialization and launch, future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, including our November 2020 private placement, the realization of expected benefits of our business combination transaction with Curetis GmbH, the success of our commercialization efforts, the impact of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. OpGen Contact:Oliver SchachtCEOInvestorRelations@opgen.com Press Contact:Matthew BretziusFischTank Marketing and PRmatt@fischtankpr.com Investor Contact:Megan PaulEdison Groupmpaul@edisongroup.com

  • OpGen, Inc. Announces $25 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules
    GlobeNewswire

    OpGen, Inc. Announces $25 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

    GAITHERSBURG, Md., Feb. 09, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, today announced it has entered into a definitive agreement with a single U.S.- based, healthcare-focused institutional investor for the purchase of (i) 2,784,184 shares of common stock (ii) 5,549,149 pre-funded warrants (the “Pre-Funded Warrants”), with each Pre-Funded Warrant exercisable for one share of common stock. The Company has also agreed to issue to the investor, in a concurrent private placement, unregistered common share purchase warrants (the “Common Warrants”) to purchase 4,166,666 shares of the Company’s common stock. Each share of common stock and accompanying Common Warrant are being sold together at a combined offering price of $3.00, and each Pre-Funded Warrant and accompanying Common Warrant are being sold together at a combined offering price of $2.99, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules. The Pre-Funded Warrants are immediately exercisable, at an exercise price of $0.01, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. The Common Warrants will have an exercise price of $3.55 per share, will be exercisable commencing on the six-month anniversary of the date of issuance, and will expire five and one half (5.5) years from the date of issuance (collectively, the “Offering”). The closing of the Offering is expected to occur on or about February 11, 2021, subject to the satisfaction of customary closing conditions. A.G.P./Alliance Global Partners is acting as sole placement agent for the Offering. This offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-236106) previously filed with and declared effective by the U.S. Securities and Exchange Commission (the “SEC”). This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. A prospectus supplement relating to the shares of common stock sold in the Offering will be filed by OpGen with the SEC. When available, copies of the prospectus supplement, together with the accompanying prospectuses, can be obtained at the SEC’s website at www.sec.gov or from A.G.P./Alliance Global Partners, 590 Madison Avenue, 28th Floor, New York, New York 10022 or by email at prospectus@allianceg.com. This press release does not constitute an offer to sell or the solicitation of an offer to buy the securities hereunder, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. ABOUT OPGEN, INC. OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. For more information, please visit www.opgen.com. FORWARD LOOKING STATEMENTS BY OPGEN: This press release includes forward looking statements regarding the Offering. These statements and other statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. For example, the expected date of closing of the Offering is a forward looking statement. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our use of proceeds from the Offering and that we may not use such proceeds effectively, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the realization of expected benefits of our business combination transaction with Curetis GmbH, the success of our commercialization efforts, the impact of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. OpGen Contact:Oliver SchachtCEOInvestorRelations@opgen.com Press Contact:Matthew BretziusFischTank Marketing and PRmatt@fischtankpr.com Investor Contact:Megan PaulEdison Groupmpaul@edisongroup.com